QT interval prolongation and with donepezil, rivastigmine and galantamine
Background: Acetylcholinesterase inhibitors (AChEis) including donepezil, galantamine and rivastigmine are used to treat Alzheimer’s disease (AD). This study aimed to evaluate evidence from the case report literature for an association between these agents and risk of QT interval prolongation and To...
Những tác giả chính: | Katie Malone, Jules C. Hancox |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
SAGE Publishing
2020-08-01
|
Loạt: | Therapeutic Advances in Drug Safety |
Truy cập trực tuyến: | https://doi.org/10.1177/2042098620942416 |
Những quyển sách tương tự
-
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
Bằng: E Loveman, et al.
Được phát hành: (2006-01-01) -
Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina
Bằng: Cristiane Bezerra da Silva, et al.
Được phát hành: (2016-01-01) -
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
Bằng: J. Bryant, et al.
Được phát hành: (2001-01-01) -
Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
Bằng: Dan-Dan Li, et al.
Được phát hành: (2019-05-01) -
Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy
Bằng: Michael Gysel, et al.
Được phát hành: (2014-01-01)